medigraphic.com
ISSN 1561-3011 (Electronic)

2012, Number 1

<< Back Next >>

Rev Cubana Invest Bioméd 2012; 31 (1)

Rabbit serum with complement activity to typify human major histocompatibility complex

Góngora AW, Sánchez AR, Torres PZ, Corella SJ, Cobos VD, Miranda CA, Dunia RT

Language: Spanish
References: 14
Page: 81-86
PDF size: 33.15 Kb.


ABSTRACT

Microlinfocitotoxicity assay is one of the serological methods used to classify human major histocompatibility complex. In this technique the rabbit´s serum as complement source, plays an essential role in antigens determination and in lymphocytes cross match assay as necessary stage before the selection of the best donor-receiver pair to realize the organ transplant. Three experimental lots of normal rabbit serum were developed with excellent indicators of efficiency, biological activity and stability. Rabbit's blood was obtained through jugulating technique and serum was separated by centrifugation in controlled environment and temperature´s conditions. The sterilization process was performed by filtration and the samples were taken for quality´s control assays. Stability studies showed that the product kept the biological activity at least during 18 months after it was processed and cytotoxicity's values were adequate for its employment in histocompatibility pre-transplant assays.


REFERENCES

  1. Bonet L, Martínez Z. Los métodos serológicos y moleculares en la tipificación de los antígenos de leucocitos humanos. Minirevisión. Bioquímica. 2004;29:126-30.

  2. Howell WM, Navarrete C. The HLA System: an update and relevance to patient donor matching strategies in clinical transplantation. Vox Sang. 1996;71:6-12.

  3. Giralt P, Urra JM, Sanabria C, Giralt J, Pérez MJ, Benito P. Biological differences on onset among type 1A diabetics in relation to HLA DQ genetic markers. Med Clin. (Barc) 2003;120:6-9.

  4. Pascual M, Mataran L, Jones G, Shing D, Van Der Slik AR, Giphart MJ, et al. HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II genes. Scan J Rheumatol. 2002;31:27-8.

  5. Mc Cluskey J, Au Peh C. The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenetics. 1999;1:3-20.

  6. Terasaki PI, McClelland JD. Micro droplet assay of human serum cytotoxins. Nature. 1964;204:998-100.

  7. Martin S, Dyer PA. Identification and importance of MHC. The definition of HLA specificities by cytotoxicity. Transplant Immunol. 1994;2:108-15.

  8. Morris PJ. Kidney transplantation. Principles and practice. 2da. ed. London: Grune & Stratton; 1984. p. 581.

  9. García LF, Arango AM, Henao JE, Arbelaez M. Blood transfusions and HLA compatibility in first cadaveric kidney transplants Irea1ed with cyclosporine A. Transpl Proc. 1988;20:715-19.

  10. Barry TS, Finn OJ. Human allograft derived T celling - donor class 1- and class Il-directed cytotoxicity and repertoire stability in sequential biopsies. Human Immune. 1988;22:185-98.

  11. Sara C, Luis F. El complejo mayor de histocompatibilidad humano. Sistema HLA. IATREIN. 1989;2:137-55.

  12. Rivero RA, Bencomo AA, Villaescusa R, Rubio R. Desarrollo de reactivos biológicos: una alternativa ventajosa 30 años después. Rev Cubana Hematol Inmunol Hemoter. 1997;12(2).

  13. Protocolo estándar para la generación de sueros policlonales en conejo. [citado 14 Dic 2010]. Disponible en: http://www.proteinalternatives.com/servicios/

  14. Gallardo JM. Técnicas y protocolos experimentales en Biomedicina. 2006. [citado 14 Dic 2010]. Disponible en: http://labtox-02.blogspot.com/2006/01/obtencion-de-suero.html




2020     |     www.medigraphic.com